

## Prevacid<sup>®</sup> SoluTab<sup>™</sup> (lansoprazole) – First-time generic

- On March 8, 2018, <u>Teva launched AB-rated</u> generic versions of Takeda's <u>Prevacid Solutab</u> (<u>lansoprazole</u>) 15 mg and 30 mg delayed-release orally disintegrating tablets.
- Prevacid SoluTab is approved for the following (consult the Prevacid SoluTab drug label for detailed information about the indications):
  - Treatment of active duodenal ulcer
  - Eradication of Helicobacter pylori to reduce the risk of duodenal ulcer recurrence
  - Maintenance of healed duodenal ulcers
  - Treatment of active benign gastric ulcer
  - Healing of nonsteroidal anti-inflammatory drug (NSAID)-associated gastric ulcer
  - Risk reduction of NSAID-associated gastric ulcer
  - Treatment of symptomatic gastroesophageal reflux disease (GERD)
  - Treatment of erosive esophagitis (EE)
  - Maintenance of healing of EE
  - Pathological hypersecretory conditions including Zollinger-Ellison syndrome (ZES).
- Lansoprazole is also available generically as <u>15 mg and 30 mg delayed-release capsules</u>, <u>over-the-counter (OTC) 15 mg delayed-release capsules</u>, and <u>30 mg delayed-release capsules in combination with amoxicillin and clarithromycin.</u>
  - Generic lansoprazole carries the same indications as Prevacid SoluTab.
  - Generic OTC lansoprazole is used to treat frequent heartburn (occurs 2 or more days a week).
  - The combination therapy is approved for H. pylori eradication to reduce the risk of duodenal ulcer recurrence.



## optumrx.com

OptumRx® specializes in the delivery, clinical management and affordability of prescription medications and consumer health products. We are an Optum® company — a leading provider of integrated health services. Learn more at **optum.com**.

All Optum® trademarks and logos are owned by Optum, Inc. All other brand or product names are trademarks or registered marks of their respective owners.

This document contains information that is considered proprietary to OptumRx and should not be reproduced without the express written consent of OptumRx.

RxNews® is published by the OptumRx Clinical Services Department.

©2018 Optum, Inc. All rights reserved.